Streetbeat News

Revenues

BTI

CNBS

CURLF

GTBIF

OGI

TCNNF

Tim Seymour, portfolio manager of the Amplify Seymour Cannabis ETF (NYSE:CNBS), discusses the growth potential in the cannabis sector, emphasizing the importance of strategic partnerships, operational efficiencies, and the burgeoning U.S. hemp cannabinoid market. He highlights companies like Curaleaf, Green Thumb Industries, and Trulieve for their strong market positions and governance. Seymour also notes British Tobacco's investment in Organigram as a strategic move to expand international market reach.

Portfolio Pulse from Nicolás Jose Rodriguez

June 17, 2024 | 1:26 pm

SLYV

SPY

A Reddit discussion highlights the need to adjust market cap definitions for inflation, as small-cap value stocks lag 20% behind the S&P 500. The SPDR S&P 600 Small Cap Value ETF (SLYV) is down 8.31% YTD, while the SPDR S&P 500 ETF (SPY) has gained 14.19%. Adjusting market cap thresholds could provide a more accurate representation of company sizes and aid in better investment decisions.

Portfolio Pulse from Surbhi Jain

June 17, 2024 | 1:22 pm

FBIO

MBIO

Mustang Bio Inc (NASDAQ:MBIO) shares surged over 190% on Monday following the announcement of positive Phase 1/2 trial results for their CAR T-cell therapy, MB-106, targeting Waldenstrom macroglobulinemia. The trial showed a 90% response rate with favorable safety outcomes. The company, founded by Fortress Biotech Inc (NASDAQ:FBIO), presented these results at the European Hematology Association 2024 Hybrid Congress.

Portfolio Pulse from Vandana Singh

June 17, 2024 | 1:21 pm

RIO

Rio Tinto (NYSE:RIO) is set to receive approval from Serbia to develop Europe's largest lithium mine, the Jadar project, by 2028. This project aims to produce significant amounts of lithium carbonate, boric acid, and sodium sulfate, crucial for the EV industry and other industrial applications. Despite past environmental concerns and opposition, new guarantees from Rio Tinto and the EU have addressed these issues, leading to the project's revival.

Portfolio Pulse from Stjepan Kalinic

June 17, 2024 | 1:12 pm

INTC

TSM

TSMC has received orders for 3nm chips from Intel for its upcoming notebook processor series, with wafer production already underway.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 1:12 pm

NVDA

NVIDIA has contributed the largest ever indoor synthetic dataset to the AI City Challenge at the CVPR conference, aiding the development of AI models for smart cities and industrial automation. The dataset, created using NVIDIA Omniverse, includes 212 hours of 1080p video and features nearly 1,000 cameras and 2,500 digital human characters. This initiative aims to enhance operational efficiency in physical settings such as retail and warehouse environments.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 1:10 pm

NVDA

NVIDIA won the Autonomous Grand Challenge at the CVPR conference with its Hydra-MDP model for end-to-end driving. The company also showcased its advancements in accelerated computing and generative AI for autonomous vehicle development, including the NVIDIA Omniverse Cloud Sensor RTX microservices.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 1:10 pm

GSK

ITOS

iTeos Therapeutics and GSK have initiated the GALAXIES Lung-301 Phase 3 study to assess the efficacy of belrestotug and dostarlimab in treating previously untreated, unresectable, locally advanced or metastatic PD-L1 selected non-small cell lung cancer. The primary endpoints are progression-free survival and overall survival.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 1:07 pm

AUTL

Analysts' ratings for Autolus Therapeutics (NASDAQ:AUTL) over the last quarter show a range of sentiments from bullish to bearish. The average 12-month price target is $9.4, with a high of $11.00 and a low of $9.00. The company's market capitalization, revenue growth, and debt management are strong, but it faces challenges with net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

June 17, 2024 | 1:00 pm

OVID

TAK

Takeda Pharmaceutical's Phase 3 studies for Soticlestat in treating Dravet syndrome and Lennox-Gastaut syndrome failed. Ovid Therapeutics, which previously sold the rights to Takeda, will update its guidance based on Takeda's next steps. Ovid's shares dropped significantly in premarket trading.

Portfolio Pulse from Vandana Singh

June 17, 2024 | 12:59 pm